These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16379242)

  • 1. [Rheumatoid arthritis: earlier and more aggressive therapies].
    Kathmann W
    Dtsch Med Wochenschr; 2005 Oct; Suppl 1():58-9. PubMed ID: 16379242
    [No Abstract]   [Full Text] [Related]  

  • 2. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R; Albert D
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
    Renato GM
    Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to citrullinated proteins in arthritis: pathology and promise.
    Klareskog L; Widhe M; Hermansson M; Rönnelid J
    Curr Opin Rheumatol; 2008 May; 20(3):300-5. PubMed ID: 18388522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are anti-cyclic citrullinated peptide antibodies pathogenic in rheumatoid arthritis?
    Holers VM
    Nat Clin Pract Rheumatol; 2006 Aug; 2(8):400-1. PubMed ID: 16932728
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The clinical significance of cyclic citrullinated peptide antibodies: new data].
    Novikov AA; Aleksandrova EN; Nasonov EL
    Klin Med (Mosk); 2007; 85(8):4-9. PubMed ID: 17926481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphomatoid granulomatosis in a patient with rheumatoid arthritis receiving methotrexate: successful treatment with the anti-CD20 antibody mabthera.
    Schalk E; Krogel C; Scheinpflug K; Mohren M
    Onkologie; 2009 Jul; 32(7):440-1. PubMed ID: 19556825
    [No Abstract]   [Full Text] [Related]  

  • 9. Long term treatment of rheumatoid arthritis with rituximab.
    Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
    Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?
    Bobbio-Pallavicini F; Caporali R; Bugatti S; Montecucco C
    J Rheumatol; 2008 Oct; 35(10):1903-5. PubMed ID: 18843754
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunomodulation in the treatment of rheumatoid arthritis].
    Vischer TL
    Ther Umsch; 1986 Feb; 43(2):144-7. PubMed ID: 3515609
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms.
    Silverman GJ
    Arthritis Rheum; 2006 Aug; 54(8):2356-67. PubMed ID: 16868991
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantitative clinical rheumatology: why is a test for anti-CCP antibodies included in most routine care for rheumatoid arthritis while a HAQ/MDHAQ remains largely a research tool?
    Pincus T; Yazici Y; Bergman MJ
    J Rheumatol; 2009 Aug; 36(8):1563-4. PubMed ID: 19671805
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis.
    Niewold TB; Harrison MJ; Paget SA
    QJM; 2007 Apr; 100(4):193-201. PubMed ID: 17434910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis.
    van Tuyl LH; Lems WF; Kerstens PJ; Voskuyl AE; Dijkmans BA; Boers M
    Ann Rheum Dis; 2009 Oct; 68(10):1652-3. PubMed ID: 19748920
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Citrullinated antigens: just diagnostic tools or pathogenic targets in rheumatoid arthritis?
    Feist E; Burmester GR
    J Rheumatol; 2006 Nov; 33(11):2103-4. PubMed ID: 17086596
    [No Abstract]   [Full Text] [Related]  

  • 18. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
    Yukawa N; Mimori T
    Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.
    Mofidi M; Moghadam A
    Saudi Med J; 2008 Aug; 29(8):1206-7. PubMed ID: 18690324
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis.
    van Venrooij WJ; van Beers JJ; Pruijn GJ
    Ann N Y Acad Sci; 2008 Nov; 1143():268-85. PubMed ID: 19076355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.